Patents by Inventor Lewis L. Lanier

Lewis L. Lanier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CMV VACCINE AND METHOD OF MAKING AND USING THE SAME
    Publication number: 20240041994
    Abstract: The present invention provides vaccine compositions for preventing and/or treating cytomegalovirus (CMV) infection and methods of making and using the same.
    Type: Application
    Filed: May 3, 2023
    Publication date: February 8, 2024
    Inventors: Lewis L. LANIER, William H. HILDEBRAND
  • CMV Vaccine and Method of Making and Using the Same
    Publication number: 20200171135
    Abstract: The present invention provides vaccine compositions for preventing and/or treating cytomegalovirus (CMV) infection and methods of making and using the same.
    Type: Application
    Filed: May 24, 2018
    Publication date: June 4, 2020
    Inventors: Lewis L. Lanier, William H. Hildebrand
  • Assessment of solid tumor burden
    Patent number: 9683996
    Abstract: The present disclosure is directed toward measurement of expression of one or both of an activating Natural Killer (NK) cell receptor and its ligand(s) on peripheral blood cells as a means to assess solid tumor burden. In particular, the present disclosure provides tools for assessing cancer recurrence or risk thereof following reduction of a solid tumor, and for developing a treatment regime for a cancer patient.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: June 20, 2017
    Assignee: The Regents of the University of California
    Inventors: Andrew T. Parsa, Lewis L. Lanier, Courtney Crane
  • MODULATION OF NKG2D
    Publication number: 20160311906
    Abstract: The present invention relates to methods and compositions for treating and/or preventing inflammation associated with viral infection and solid organ transplant rejection. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
    Type: Application
    Filed: March 25, 2016
    Publication date: October 27, 2016
    Applicant: The Regents of the University of California
    Inventors: Lewis L. LANIER, Koetsu OGASAWARA, Jeffrey A. BLUESTONE
  • Modulation of NKG2D for prolonging survival of a hematopoietic graft
    Patent number: 9211328
    Abstract: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: December 15, 2015
    Assignee: The Regents of the University of California
    Inventors: Lewis L. Lanier, Koetsu Ogasawara, Jeffrey A. Bluestone
  • Isolated Mammalian Monocyte Cell Genes; Related Reagents
    Publication number: 20140141445
    Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • Isolated Mammalian Monocyte Cell Genes; Related Reagents
    Publication number: 20140141444
    Abstract: DNA clones encoding a receptor in the Ig superfamily and a related soluble variant have been isolated from a human monocyte library. The invention provides receptor polypeptides, nucleic acids encoding them, expression vectors, and transformed cells for recombinant production of the polypeptides.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • Modulation of NKG2D
    Patent number: 8637011
    Abstract: The present invention relates to methods and compositions for treating and/or preventing inflammation associated with viral infection and solid organ transplant rejection. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: January 28, 2014
    Assignee: The Regents of The University of California
    Inventors: Jody L. Baron, Lewis L. Lanier
  • ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS
    Publication number: 20130034561
    Abstract: Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Application
    Filed: October 12, 2012
    Publication date: February 7, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips
  • ASSESSMENT OF SOLID TUMOR BURDEN
    Publication number: 20120322668
    Abstract: The present disclosure is directed toward measurement of expression of one or both of an activating Natural Killer (NK) cell receptor and its ligand(s) on peripheral blood cells as a means to assess solid tumor burden. In particular, the present disclosure provides tools for assessing cancer recurrence or risk thereof following reduction of a solid tumor, and for developing a treatment regime for a cancer patient.
    Type: Application
    Filed: October 22, 2010
    Publication date: December 20, 2012
    Applicant: The Regents of the University of California
    Inventors: Andrew T. Parsa, Lewis L. Lanier, Courtney Crane
  • Ox2 Receptor Homologs
    Publication number: 20120231003
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Application
    Filed: March 16, 2012
    Publication date: September 13, 2012
    Applicants: Medical Research Council, Schering Corporation
    Inventors: A. Neil Barclay, Marion H. Brown, Daniel M. Gorman, Lewis L. Lanier, Gavin J. Wright, Holly Cherwinski, Joseph H. Phillips, Robert M. Hoek, Jonathan D. Sedgwick
  • MODULATION OF NKG2D
    Publication number: 20120064070
    Abstract: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
    Type: Application
    Filed: July 6, 2011
    Publication date: March 15, 2012
    Applicant: The Regents of the University of California
    Inventors: Lewis L. Lanier, Koetsu Ogasawara, Jeffrey A. Bluestone
  • ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS
    Publication number: 20120020990
    Abstract: Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Application
    Filed: July 25, 2011
    Publication date: January 26, 2012
    Applicant: Schering Corporation
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips, JR.
  • Antibodies that bind DNAX leukocyte associated immunoglobulin-like receptor
    Patent number: 7999078
    Abstract: Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using reagents and related diagnostic kits are also provided.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: August 16, 2011
    Assignee: Schering Corporation
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips, Jr.
  • Modulation of NKG2D for treating or preventing solid organ allograft rejection
    Patent number: 7998481
    Abstract: The present invention relates to methods and compositions for treating and/or preventing autoimmune and/or inflammatory disease. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: August 16, 2011
    Assignee: The Regents of the University of California
    Inventors: Sang-Mo Kang, Lewis L. Lanier
  • ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS
    Publication number: 20100209907
    Abstract: Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided.
    Type: Application
    Filed: November 5, 2008
    Publication date: August 19, 2010
    Inventors: Gosse Jan Adema, Linde Meyaard, Daniel M. Gorman, Terrill K. McClanahan, Sandra M. Zurawski, Gerard Zurawski, Lewis L. Lanier, Joseph H. Phillips, JR.
  • MODULATION OF NKG2D
    Publication number: 20100183591
    Abstract: The present invention relates to methods and compositions for treating and/or preventing inflammation associated with viral infection and solid organ transplant rejection. In particular, the present invention provides therapeutics for impairing the expansion and function of autoreactive T cells, NK cells and/or NKT cells, by modulating NKG2D.
    Type: Application
    Filed: May 4, 2007
    Publication date: July 22, 2010
    Applicant: Regents of the University of California
    Inventors: Jody L. Baron, Sang-Mo Kang, Lewis L. Lanier
  • Mammalian Cell Membrane Proteins; Related Reagents
    Publication number: 20100129374
    Abstract: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.
    Type: Application
    Filed: January 25, 2010
    Publication date: May 27, 2010
    Applicant: SCHERING CORPORATION
    Inventors: Alexander B.H. Bakker, Joseph H. Phillips, Lewis L. Lanier
  • DAP12 nucleic acids
    Patent number: 7659093
    Abstract: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: February 9, 2010
    Assignee: Schering Corporation
    Inventors: Alexander B. H. Bakker, Joseph H. Phillips, Lewis L. Lanier
  • MAMMALIAN CELL MEMBRANE PROTEINS; RELATED REAGENTS
    Publication number: 20090263403
    Abstract: The purification and isolation of various genes which encode mammalian cell surface polypeptides. Nucleic acids, proteins, antibodies, and other reagents useful in modulating development of cells, e.g., lymphoid and myeloid, are provided, along with methods for their use.
    Type: Application
    Filed: June 26, 2009
    Publication date: October 22, 2009
    Applicant: SCHERING CORPORATION
    Inventors: Alexander B.H. Bakker, Joseph H. Phillips, Lewis L. Lanier